5-hydroxymethylcytosine and its potential roles in development and cancer

Epigenetics and Chromatin

Volumn 6, Issue 1, 2013, Pages

  Pfeifer, Gerd P ^a   Kadam, Swati ^a   Jin, Seung Gi ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; 5 HYDROXYMETHYLCYTOSINE; 5 METHYLCYTOSINE; DNA BASE; DNA METHYLTRANSFERASE 1; ISOCITRATE DEHYDROGENASE; METHYL CPG BINDING PROTEIN; OXIDOREDUCTASE; TEN ELEVEN TRANSLOCATION 1; THYMINE DNA GLYCOSYLASE; UNCLASSIFIED DRUG;

ALLELE; CELL PROLIFERATION; CPG ISLAND; DECARBOXYLATION; DNA METHYLATION; DNA REPLICATION; EPIGENETICS; EXCISION REPAIR; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; MYELOPROLIFERATIVE NEOPLASM; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW;

MAMMALIA;

EID: 84876794613     PISSN: None     EISSN: 17568935     Source Type: Journal    
DOI: 10.1186/1756-8935-6-10     Document Type: Review

References (89)

1. Mammalian cytosine methylation at a glance. Ooi SK, O'Donnell AH, Bestor TH, J Cell Sci 2009 122 2787 2791 10.1242/jcs.015123 19657014
2. Genomic DNA methylation: the mark and its mediators. Klose RJ, Bird AP, Trends Biochem Sci 2006 31 89 97 10.1016/j.tibs.2005.12.008 16403636 (Pubitemid 43221841)
3. Nucleic acid economy in bacteria infected with bacteriophage T2. I. Purine and pyrimidine composition. Hershey AD, Dixon J, Chase M, J Gen Physiol 1953 36 777 789 10.1085/jgp.36.6.777 13069681
4. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Penn NW, Suwalski R, O'Riley C, Bojanowski K, Yura R, Biochem J 1972 126 781 790 4538516
5. 5-Methylcytosine content in the vertebrate deoxyribonucleic acids: species specificity. Kothari RM, Shankar V, J Mol Evol 1976 7 325 329 10.1007/BF01743628 933178
6. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. Globisch D, Munzel M, Muller M, Michalakis S, Wagner M, Koch S, Bruckl T, Biel M, Carell T, PLoS One 2010 5 15367 10.1371/journal.pone.0015367 21203455
7. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Kriaucionis S, Heintz N, Science 2009 324 929 930 10.1126/science.1169786 19372393
8. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A, Science 2009 324 930 935 10.1126/science.1170116 19372391
9. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Ono R, Taki T, Taketani T, Taniwaki M, Kobayashi H, Hayashi Y, Cancer Res 2002 62 4075 4080 12124344 (Pubitemid 34791077)
10. Genomic mapping of 5-hydroxymethylcytosine in the human brain. Jin SG, Wu X, Li AX, Pfeifer GP, Nucleic Acids Res 2011 39 5015 5024 10.1093/nar/gkr120 21378125
11. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Münzel M, Globisch D, Bruckl T, Wagner M, Welzmiller V, Michalakis S, Muller M, Biel M, Carell T, Angew Chem Int Ed Engl 2010 49 5375 5377 10.1002/anie.201002033 20583021
12. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Song CX, Szulwach KE, Fu Y, Dai Q, Yi C, Li X, Li Y, Chen CH, Zhang W, Jian X, Wang J, Zhang L, Looney TJ, Zhang B, Godley LA, Hicks LM, Lahn BT, Jin P, He C, Nat Biotechnol 2011 29 68 72 10.1038/nbt.1732 21151123
13. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Wu H, Zhang Y, Genes Dev 2011 25 2436 2452 10.1101/gad.179184.111 22156206
14. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Guo JU, Su Y, Zhong C, Ming GL, Song H, Cell Cycle 2011 10 2662 2668 10.4161/cc.10.16.17093 21811096
15. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Valinluck V, Sowers LC, Cancer Res 2007 67 946 950 10.1158/0008-5472.CAN-06-3123 17283125
16. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Hashimoto H, Liu Y, Upadhyay AK, Chang Y, Howerton SB, Vertino PM, Zhang X, Cheng X, Nucleic Acids Res 2012 40 4841 4849 10.1093/nar/gks155 22362737
17. The mammalian de novo DNA methyltransferases DNMT3A and DNMT3B are also DNA 5-hydroxymethylcytosine dehydroxymethylases. Chen CC, Wang KY, Shen CK, J Biol Chem 2012 287 33116 33121 10.1074/jbc.C112.406975 22898819
18. An unexpectedly high excision capacity for mispaired 5- hydroxymethyluracil in human cell extracts. Rusmintratip V, Sowers LC, Proc Natl Acad Sci U S A 2000 97 14183 14187 10.1073/pnas.97.26.14183 11121024 (Pubitemid 32016551)
19. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, Le Coz M, Devarajan K, Wessels A, Soprano D, Abramowitz LK, Bartolomei MS, Rambow F, Bassi MR, Bruno T, Fanciulli M, Renner C, Klein-Szanto AJ, Matsumoto Y, Kobi D, Davidson I, Alberti C, Larue L, Bellacosa A, Cell 2011 146 67 79 10.1016/j.cell.2011.06.020 21722948
20. Excision of 5-hydroxymethyluracil and 5-carboxylcytosine by the thymine DNA glycosylase domain: its structural basis and implications for active DNA demethylation. Hashimoto H, Hong S, Bhagwat AS, Zhang X, Cheng X, Nucleic Acids Res 2012 40 10203 10214 10.1093/nar/gks845 22962365
21. Definitive identification of mammalian 5-hydroxymethyluracil DNA N-glycosylase activity as SMUG1. Boorstein RJ, Cummings A Jr, Marenstein DR, Chan MK, Ma Y, Neubert TA, Brown SM, Teebor GW, J Biol Chem 2001 276 41991 41997 10.1074/jbc.M106953200 11526119 (Pubitemid 37371101)
22. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, He C, Zhang Y, Science 2011 333 1300 1303 10.1126/science.1210597 21778364
23. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, Ding J, Jia Y, Chen Z, Li L, Sun Y, Li X, Dai Q, Song CX, Zhang K, He C, Xu GL, Science 2011 333 1303 1307 10.1126/science.1210944 21817016
24. Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Schiesser S, Hackner B, Pfaffeneder T, Muller M, Hagemeier C, Truss M, Carell T, Angew Chem Int Ed Engl 2012 51 6516 6520 10.1002/anie.201202583 22644704
25. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Jin SG, Kadam S, Pfeifer GP, Nucleic Acids Res 2010 38 125 10.1093/nar/gkq223 20371518
26. Recognition of 5-hydroxymethylcytosine by the Uhrf1 SRA domain. Frauer C, Hoffmann T, Bultmann S, Casa V, Cardoso MC, Antes I, Leonhardt H, PLoS One 2011 6 21306 10.1371/journal.pone.0021306 21731699
27. Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Yildirim O, Li R, Hung JH, Chen PB, Dong X, Ee LS, Weng Z, Rando OJ, Fazzio TG, Cell 2011 147 1498 1510 10.1016/j.cell.2011.11. 054 22196727
28. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Mellen M, Ayata P, Dewell S, Kriaucionis S, Heintz N, Cell 2012 151 1417 1430 10.1016/j.cell.2012.11.022 23260135
29. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Spruijt CG, Gnerlich F, Smits AH, Pfaffeneder T, Jansen PW, Bauer C, Munzel M, Wagner M, Muller M, Khan F, Eberl HC, Mensinga A, Brinkman AB, Lephikov K, Muller U, Walter J, Boelens R, van Ingen H, Leonhardt H, Carell T, Vermeulen M, Cell 2013 152 1146 1159 10.1016/j.cell.2013.02.004 23434322
30. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Iqbal K, Jin SG, Pfeifer GP, Szabo PE, Proc Natl Acad Sci U S A 2011 108 3642 3647 10.1073/pnas.1014033108 21321204
31. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Wossidlo M, Nakamura T, Lepikhov K, Marques CJ, Zakhartchenko V, Boiani M, Arand J, Nakano T, Reik W, Walter J, Nat Commun 2011 2 241 21407207
32. Demethylation of the zygotic paternal genome. Mayer W, Niveleau A, Walter J, Fundele R, Haaf T, Nature 2000 403 501 502 10676950 (Pubitemid 30082186)
33. Active demethylation of the paternal genome in the mouse zygote. Oswald J, Engemann S, Lane N, Mayer W, Olek A, Fundele R, Dean W, Reik W, Walter J, Curr Biol 2000 10 475 478 10.1016/S0960-9822(00)00448-6 10801417 (Pubitemid 30247337)
34. PGC7 binds histone H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos. Nakamura T, Liu YJ, Nakashima H, Umehara H, Inoue K, Matoba S, Tachibana M, Ogura A, Shinkai Y, Nakano T, Nature 2012 486 415 419 22722204
35. H3K9me2 attracts PGC7 in the zygote to prevent Tet3-mediated oxidation of 5-methylcytosine. Szabo PE, Pfeifer GP, J Mol Cell Biol 2012 4 427 429 10.1093/jmcb/mjs038 22750790
36. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Gu TP, Guo F, Yang H, Wu HP, Xu GF, Liu W, Xie ZG, Shi L, He X, Jin SG, Iqbal K, Shi YG, Deng Z, Szabo PE, Pfeifer GP, Li J, Xu GL, Nature 2011 477 606 610 10.1038/nature10443 21892189
37. Epigenetic reprogramming in plant and animal development. Feng S, Jacobsen SE, Reik W, Science 2010 330 622 627 10.1126/science.1190614 21030646
38. Parallel mechanisms of epigenetic reprogramming in the germline. Hackett JA, Zylicz JJ, Surani MA, Trends Genet 2012 28 164 174 10.1016/j.tig.2012.01.005 22386917
39. The dynamics of genome-wide DNA methylation reprogramming in mouse primordial germ cells. Seisenberger S, Andrews S, Krueger F, Arand J, Walter J, Santos F, Popp C, Thienpont B, Dean W, Reik W, Mol Cell 2012 48 849 862 10.1016/j.molcel.2012.11.001 23219530
40. The simplest explanation: passive DNA demethylation in PGCs. Smith ZD, Meissner A, EMBO J 2013 32 318 321 10.1038/emboj.2012.349 23299938
41. Replication-coupled passive DNA demethylation for the erasure of genome imprints in mice. Kagiwada S, Kurimoto K, Hirota T, Yamaji M, Saitou M, EMBO J 2013 32 340 353 23241950
42. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA, Surani MA, Science 2013 339 448 452 10.1126/science.1229277 23223451
43. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. Hajkova P, Jeffries SJ, Lee C, Miller N, Jackson SP, Surani MA, Science 2010 329 78 82 10.1126/science.1187945 20595612
44. Combined deficiency of Tet1 and Tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dawlaty MM, Breiling A, Le T, Raddatz G, Barrasa MI, Cheng AW, Gao Q, Powell BE, Li Z, Xu M, Faull KF, Lyko F, Jaenisch R, Dev Cell 2013 24 310 323 10.1016/j.devcel.2012.12.015 23352810
45. Tet-assisted bisulfite sequencing of 5-hydroxymethylcytosine. Yu M, Hon GC, Szulwach KE, Song CX, Jin P, Ren B, He C, Nat Protoc 2012 7 2159 2170 10.1038/nprot.2012.137 23196972
46. Genome-wide erasure of DNA methylation in mouse primordial germ cells is affected by AID deficiency. Popp C, Dean W, Feng S, Cokus SJ, Andrews S, Pellegrini M, Jacobsen SE, Reik W, Nature 2010 463 1101 1105 10.1038/nature08829 20098412
47. 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Jin SG, Jiang Y, Qiu R, Rauch TA, Wang Y, Schackert G, Krex D, Lu Q, Pfeifer GP, Cancer Res 2011 71 7360 7365 10.1158/0008-5472.CAN-11-2023 22052461
48. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Szulwach KE, Li X, Li Y, Song CX, Wu H, Dai Q, Irier H, Upadhyay AK, Gearing M, Levey AI, Vasanthakumar A, Godley LA, Chang Q, Cheng X, He C, Jin P, Nat Neurosci 2011 14 1607 1616 10.1038/nn.2959 22037496
49. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Williams K, Christensen J, Pedersen MT, Johansen JV, Cloos PA, Rappsilber J, Helin K, Nature 2011 473 343 348 10.1038/nature10066 21490601
50. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, Marques CJ, Andrews S, Reik W, Nature 2011 473 398 402 10.1038/nature10008 21460836
51. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Nestor CE, Ottaviano R, Reddington J, Sproul D, Reinhardt D, Dunican D, Katz E, Dixon JM, Harrison DJ, Meehan RR, Genome Res 2012 22 467 477 10.1101/gr.126417.111 22106369
52. Differential effect of three base modifications on DNA thermostability revealed by high resolution melting. Lopez CM, Lloyd AJ, Leonard K, Wilkinson MJ, Anal Chem 2012 84 7336 7342 10.1021/ac301459x 22882125
53. Discrimination of methylcytosine from hydroxymethylcytosine in DNA molecules. Wanunu M, Cohen-Karni D, Johnson RR, Fields L, Benner J, Peterman N, Zheng Y, Klein ML, Drndic M, J Am Chem Soc 2011 133 486 492 10.1021/ja107836t 21155562
54. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY, Nat Genet 1999 23 185 188 10.1038/13810 10508514 (Pubitemid 29455390)
55. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC, Nucleic Acids Res 2004 32 4100 4108 10.1093/nar/gkh739 15302911 (Pubitemid 39232282)
56. Dynamics of 5-hydroxymethylcytosine and chromatin marks in mammalian neurogenesis. Hahn MA, Qiu R, Wu X, Li AX, Zhang H, Wang J, Jui J, Jin SG, Jiang Y, Pfeifer GP, Lu Q, Cell Rep 2013 3 291 300 10.1016/j.celrep.2013.01.011 23403289
57. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG, Toubaji A, Argani P, Iacobuzio-Donahue C, Nelson WG, Netto GJ, De Marzo AM, Yegnasubramanian S, Oncotarget 2011 2 627 637 21896958
58. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y, Oncogene 2013 32 663 669 10.1038/onc.2012.67 22391558
59. Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base", are associated with anaplasia in human brain tumors. Kraus TF, Globisch D, Wagner M, Eigenbrod S, Widmann D, Munzel M, Muller M, Pfaffeneder T, Hackner B, Feiden W, Schuller U, Carell T, Kretzschmar HA, Int J Cancer 2012 131 1577 1590 10.1002/ijc.27429 22234893
60. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, Nagae G, Yoshida H, Aburatani H, Koike K, Cancer Sci 2012 103 670 676 10.1111/j.1349-7006.2012.02213.x 22320381
61. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG, Cell 2012 150 1135 1146 10.1016/j.cell.2012.07.033 22980977
62. Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Inoue A, Zhang Y, Science 2011 334 194 10.1126/science.1212483 21940858
63. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y, Nature 2010 466 1129 1133 10.1038/nature09303 20639862
64. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Iyer LM, Tahiliani M, Rao A, Aravind L, Cell Cycle 2009 8 1698 1710 10.4161/cc.8.11.8580 19411852
65. Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Xu Y, Xu C, Kato A, Tempel W, Abreu JG, Bian C, Hu Y, Hu D, Zhao B, Cerovina T, Diao J, Wu F, He HH, Cui Q, Clark E, Ma C, Barbara A, Veenstra GJ, Xu G, Kaiser UB, Liu XS, Sugrue SP, He X, Min J, Kato Y, Shi YG, Cell 2012 151 1200 1213 10.1016/j.cell.2012.11.014 23217707
66. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Ko M, An J, Bandukwala HS, Chavez L, Aijo T, Pastor WA, Segal MF, Li H, Koh KP, Lahdesmaki H, Hogan PG, Aravind L, Rao A, Nature 2013 in press
67. Leukaemogenesis: more than mutant genes. Chen J, Odenike O, Rowley JD, Nat Rev Cancer 2010 10 23 36 10.1038/nrc2765 20029422
68. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M, Malinge S, Yao J, Kilpivaara O, Bhat R, Huberman K, Thomas S, Dolgalev I, Heguy A, Paietta E, Le Beau MM, Beran M, Tallman MS, Ebert BL, Kantarjian HM, Stone RM, Gilliland DG, Crispino JD, Levine RL, Blood 2009 114 144 147 10.1182/blood-2009-03-210039 19420352
69. Acquired mutations in TET2 are common in myelodysplastic syndromes. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH, Nat Genet 2009 41 838 842 10.1038/ng.391 19483684
70. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguie F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M, Blood 2009 114 3285 3291 10.1182/blood-2009-04-215814 19666869
71. Mutation in TET2 in myeloid cancers. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Masse A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lecluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguie F, Fontenay M, Vainchenker W, Bernard OA, N Engl J Med 2009 360 2289 2301 10.1056/NEJMoa0810069 19474426
72. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP, Blood 2009 113 6403 6410 10.1182/blood-2009-02-205690 19372255
73. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A, Cancer Cell 2010 18 553 567 10.1016/j.ccr.2010.11.015 21130701
74. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, Figueroa ME, Vasanthakumar A, Patel J, Zhao X, Perna F, Pandey S, Madzo J, Song C, Dai Q, He C, Ibrahim S, Beran M, Zavadil J, Nimer SD, Melnick A, Godley LA, Aifantis I, Levine RL, Cancer Cell 2011 20 11 24 10.1016/j.ccr.2011.06.001 21723200
75. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, Do Cruzeiro M, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, Tilly H, Solary E, Duffourd Y, Dessen P, Merle-Beral H, Nguyen-Khac F, Fontenay M, Vainchenker W, Bastard C, Mercher T, Bernard OA, Cancer Cell 2011 20 25 38 10.1016/j.ccr.2011. 06.003 21723201
76. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M, Blood 2011 118 4509 4518 10.1182/blood-2010-12-325241 21803851
77. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, Tsangaratou A, Rajewsky K, Koralov SB, Rao A, Proc Natl Acad Sci U S A 2011 108 14566 14571 10.1073/pnas.1112317108 21873190
78. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A, Nature 2010 468 839 843 10.1038/nature09586 21057493
79. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. Perez C, Martinez-Calle N, Martin-Subero JI, Segura V, Delabesse E, Fernandez-Mercado M, Garate L, Alvarez S, Rifon J, Varea S, Boultwood J, Wainscoat JS, Cruz Cigudosa J, Calasanz MJ, Cross NC, Prosper F, Agirre X, PLoS One 2012 7 31605 10.1371/journal.pone.0031605 22328940
80. The role of mutations in epigenetic regulators in myeloid malignancies. Shih AH, Abdel-Wahab O, Patel JP, Levine RL, Nat Rev Cancer 2012 12 599 612 10.1038/nrc3343 22898539
81. TET2 and DNMT3A mutations in human T-cell lymphoma. Couronne L, Bastard C, Bernard OA, N Engl J Med 2012 366 95 96 10.1056/NEJMc1111708 22216861
82. IDH1 and IDH2 mutations in gliomas. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD, N Engl J Med 2009 360 765 773 10.1056/NEJMoa0808710 19228619
83. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Yen KE, Bittinger MA, Su SM, Fantin VR, Oncogene 2010 29 6409 6417 10.1038/onc.2010.444 20972461
84. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM, Nature 2009 462 739 744 10.1038/nature08617 19935646
85. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y, Cancer Cell 2011 19 17 30 10.1016/j.ccr.2010.12.014 21251613
86. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K, Cancer Cell 2010 17 510 522 10.1016/j.ccr.2010.03.017 20399149
87. CpG island methylator phenotype in colorectal cancer. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP, Proc Natl Acad Sci U S A 1999 96 8681 8686 10.1073/pnas.96.15.8681 10411935 (Pubitemid 29354851)
88. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA, Nature 2012 483 479 483 10.1038/nature10866 22343889
89. IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Sasaki M, Knobbe CB, Munger JC, Lind EF, Brenner D, Brustle A, Harris IS, Holmes R, Wakeham A, Haight J, You-Ten A, Li WY, Schalm S, Su SM, Virtanen C, Reifenberger G, Ohashi PS, Barber DL, Figueroa ME, Melnick A, Zuniga-Pflucker JC, Mak TW, Nature 2012 488 656 659 10.1038/nature11323 22763442